Adrian Rawcliffe - Jan 16, 2024 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Signature
/s/ Adrian George Rawcliffe
Stock symbol
ADAP
Transactions as of
Jan 16, 2024
Transactions value $
-$27,594
Form type
4
Date filed
1/17/2024, 05:31 PM
Previous filing
Jan 17, 2024
Next filing
Aug 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADAP American Depositary Shares representing Ordinary Shares Sale -$7.35K -9.3K -39.75% $0.79 14.1K Jan 16, 2024 Direct F1, F2, F3
transaction ADAP American Depositary Shares representing Ordinary Shares Sale -$20.2K -30.1K -40.15% $0.67 44.8K Jan 17, 2024 Direct F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
F2 The price reported in Column 4 is the sale price per ADS.
F3 The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 206,854 ADSs and RSU-style options and other options covering an aggregate of 35,756,832 ordinary shares of the Issuer.
F4 Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
F5 The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
F6 The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 206,854 ADSs and RSU-style options and other options covering an aggregate of 35,756,832 ordinary shares of the Issuer.